Britain and America have forged a significant trade agreement that will maintain no duties on UK pharmaceutical products going into the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise funding on pharmaceuticals through the National Health Service (NHS). This move guarantees that import taxes on these crucial exports will stay at nothing for a period of 36 months.
This deal follows earlier warnings to hike duties on patented drug imports, with increases floated as high as 100%.
"This deal with the Britain reinforces the international landscape for innovative medicines and brings long-overdue balance to U.S.–U.K. medicine commerce," an announcement said.
Commercial Significance
Drugs are one of the the United Kingdom's most significant export categories to the US, which is easily the primary buyer for large British pharmaceutical firms.
Export figures indicate that in the year to the end of last September, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount accounted for a significant portion of all goods exports in that period.
"This agreement protects jobs, increases capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a government official commented.
Detailed UK Commitments
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must return to the NHS to control costs will be limited at fifteen percent. Previously, rebates topped twenty percent.
Recent Tensions
The pact follows a ongoing tension between the drug companies and the ministers over spending levels and approval rates.
These tensions were heightened by claims that American consumers were charged significantly more for the identical medicines than consumers in the other developed nations.
Recently, several significant drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its total funding over the past decade.
